An Open-Label, Phase 2 Efficacy Study With Window of Opportunity Immune Assessment of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Phase of Trial: Phase II
Latest Information Update: 22 Jan 2018
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 16 Jan 2018 Planned End Date changed from 1 Jun 2019 to 1 Jun 2020.
- 16 Jan 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Jun 2019.
- 16 Dec 2016 New trial record